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KEYWORDS	
	 Three	 simple,	 sensitive	 and	 accurate	 spectrophotometric	 methods	 (A,	 B	 and	 C)	 were
developed	 to	 determine	 doxofylline	 in	 bulk	 and	 in	 its	 dosage	 forms.	Method	 A	 is	 based	 on
charge‐transfer	complex	formation	of	the	drug	with	p‐chloranilic	acid.	Method	B	involves	the
formation	of	colored	chloroform	extractable	ion‐pair	complex	of	the	drug	with	bromophenol
blue	under	acidic	condition.	Method	C	is	based	on	ternary	complex	formation	of	the	drug	with
molybdenum(V)	 thiocyanate	 binary	 complex.	 The	 colored	 products	 are	 quantitated
spectrophotometrically	 at	 540,	 390	 and	 690	 nm	 by	methods	 A,	 B	 and	 C,	 respectively.	 The
variables,	 which	 affected	 the	 reactions	 were	 carefully	 studied	 and	 optimized.	 The	 linear
ranges	for	the	proposed	methods	were	4‐32	μg/mL	(method	A	&	B)	and	2‐16	μg/mL	(method
C).	Analytical	performance	of	the	methods	was	statistically	validated.	The	proposed	methods
were	successfully	applied	to	the	analysis	of	doxofylline	in	its	dosage	forms	and	were	found	to
be	comparable	with	that	of	reference	method.	
Doxofylline	
Ion	association	complex	
Charge	transfer	complex	
Ternary	complex	
Spectrophotometric	analysis	
Doxofylline	analysis	
	
1.	Introduction	
	
Doxofylline	 (DFL)	 [1‐5],	 chemically	 known	 as	 7‐(1,3‐
dioxolan‐2‐ylmethyl)‐1,3‐dimethylpurine‐2,6‐dione	 (Figure	 1),	
is	 a	novel	 bronchodilator	 xanthine	derivative	drug,	used	 in	 the	
treatment	 of	 bronchial	 asthma,	 chronic	 obstructive	 pulmonary	
disease	 (COPD)	 and	 chronic	 bronchitis.	 Animal	 and	 human	
studies	 have	 shown	 similar	 efficacy	 to	 theophylline	 but	 with	
significantly	 less	 side	 effects	 [6].	 DFL	 differs	 from	 theophylline	
for	the	presence	of	a	dioxalane	group	in	position	7.	DFL	acts	as	a	
phosphodiesterase	 inhibitor	 and	 have	 decreased	 affinities	
toward	 adenosine	A1	 and	A2	 receptors	which	may	 account	 for	
the	 better	 safety	 profile	 of	 the	 drug	 [7,	 8].	 The	 safety	 profile	
shows	a	better	 tolerability	on	cardiovascular,	digestive	 and	 the	
central	 nervous	 systems	 [9].	 DFL	was	 found	 to	 be	 particularly	
effective	in	both	decreasing	the	daily	asthma	attack	rate	as	well	
as	the	beta‐2‐	agonist	consumption.	
	
 
	
	
Figure	1.		Structure	of	doxofylline.	
The	determination	of	DFL	in	pharmaceutical	preparations	is	
very	important	for	safety	and	quality	assurance.	Various	types	of	
analytical	 procedures	 have	 been	 proposed	 for	 the	 analysis	 of	
DFL	 in	 bulk,	 pharmaceutical	 formulations	 and	 biological	 fluids.	
These	procedures	include	HPLC	[10‐13],	Stability	indicating	RP‐
HPLC	chromatography	[14],	LC‐MS/MS	[15],	stability	 indicating	
HPTLC	[16].	The	above	mentioned	techniques	are	sensitive	but	
require	 sophisticated	 equipment,	 tedious	 sample	 preparation	
and	 laborious	 clean	 up	 procedure	 prior	 to	 analysis.	 Visible	
spectrophotometry	 is	 considered	 the	 most	 widely	 used	
technique,	because	of	 its	 inherent	simplicity,	 low	cost	and	wide	
availability	in	most	quality	control	 laboratories.	Therefore,	they	
are	a	 frequent	choice	for	pharmaceutical	analyses.	Kamila	et	al.	
[17]	 and	 Joshi	et	al.	 [10]	have	 reported	UV	spectrophotometric	
method	 for	 the	 quantification	 of	 DFL	 in	 pharmaceutical	
formulations.	 The	 literature	 is	 still	 poor	 in	 visible	
spectrophotometric	 methods	 for	 the	 determination	 of	 DFL	 in	
dosage	forms.	
Charge‐transfer	 complex	 results	 from	 a	 donor‐acceptor	
mechanism	 of	 Lewis	 acid‐base	 reaction	 between	 two	 or	 more	
different	chemical	constituents.	The	formation	of	charge‐transfer	
complex	 can	 be	 rapidly	 assessed	 for	 its	 validity	 as	 a	 simple	
quantitative	analytical	method	for	many	drug	substances	which	
can	 act	 as	 electron	 donors.	 p‐Chloranilic	 acid	 (π	 acceptor)	 has	
been	 investigated	 spectrophotometrically	 and	 has	 been	
successfully	utilized	in	the	determination	of	a	variety	of	electron‐
donating	basic	compounds	[18‐27].	
Ternary	 complex	 refers	 to	 a	 complex	 containing	 three	
different	molecules,	bound	together.	The	general	formula	of	the	
ternary	 complex	 denoted	 here	 as	 L‐S‐D	 (ligand	 L	 is	 the	
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investigated	drug,	 the	second	ligand	S	 is	SCN¯	and	D	is	Mo)	has	
been	widely	used	in	spectrophotometric	analysis	of	some	drugs	
like	 chloroquine	 and	 pyrimethamine	 [28],	 ampicillin,	
dicloxacillin,	 flucloxacillin	 and	 amoxicillin	 [29],	 trazodone,	
amineptine	 and	 amitriptyline	 hydrochloride	 [30],	
metoclopramide	 and	 oxybuprocaine	 [31],	 and	 some	 H1‐
antihistaminics	 [32]	 in	 pharmaceutical	 preparations	 using	
Mo(V)thiocyanate	reagent.	
The	ion‐pair	complex	is	a	special	form	of	molecular	complex	
resulting	 from	 two	 oppositely	 charged	 ions	 extractable	 into	
organic	solvents	from	aqueous	phase	at	suitable	pH.	The	ion‐pair	
extractive	spectrophotometry	has	been	applied	to	the	estimation	
of	numerous	compounds;	possessing	basic	moieties	 (secondary	
or	 tertiary	 amino	 group)	 by	 using	 an	 anionic	 dye	 as	 a	 reagent	
and	organic	solvent	as	an	extractant.	Bromophenol	blue	being	an	
anionic	dye	has	been	reported	to	 form	 ion‐pair	complexes	 thus	
offering	 simple	 and	 rapid	 spectrophotometric	 determination	of	
therapeutically	significant	pharmaceutical	compounds	[33‐43].	
However,	 the	 reaction	between	DFL	 and	p‐Chloranilic	 acid,	
Mo(V)thiocyanate	 reagent	 &	 bromophenol	 blue	 hasn’t	 been	
investigated	 yet.	 This	 paper	 describes	 three	 visible	 spectro‐
photometric	methods	 for	 the	 assay	 of	 DFL	 in	 pure	 and	 dosage	
forms.	 Method	 A	 is	 based	 on	 charge	 transfer	 complexation	
between	the	drug	as	n‐electron	donor	and	p‐chloranilic	acid	as	π	
acceptor.	Method	B	utilizes	the	formation	of	an	ion‐pair	complex	
of	the	drug	with	bromophenol	blue	and	subsequent	extraction	of	
the	yellow	color	 into	chloroform.	Method	C	 is	based	on	 ternary	
complex	formation	of	the	drug	with	molybdenum(V)thiocyanate	
binary	 complex.	 The	 proposed	 methods	 are	 optimized	 and	
validated	as	per	the	International	conference	on	Hormonisation	
guidelines	[44].	
	
2.	Experimental	
	
2.1.	Instrumentation	
	
An	 ELICO	 double	 beam	 model	 SL	 159	 digital	
spectrophotometer	with	1‐cm	matched	quartz	cells	was	used	for	
all	absorbance	measurements.	
	
2.2.	Materials	and	reagents	
	
All	 chemicals	used	were	of	 analytical	 reagent	 grade	 and	 all	
solutions	were	freshly	prepared	in	doubly	distilled	water.	
	
2.2.1.	Method	A	
	
0.2%	 p‐Chloranilic	 acid:	 Prepared	 by	 dissolving	 200	mg	 of				
p‐chloranilic	acid	(Merck,	Mumbai)	in	50	mL	propyl	alcohol	and	
make	up	to	100	mL	with	chloroform	(Merck,	Mumbai).	
	
2.2.2.	Method	B	
	
0.2%	Bromophenol	blue:	Prepared	by	dissolving	200	mg	of	
bromophenol	blue	(Sdfine‐Chem	limited,	Mumbai)	in	100	mL	of	
distilled	 water.	 0.5	 N	 HCl:	 1.825	 mL	 of	 HCl	 (Fisher	 Scientific,	
Mumbai)	was	added	to	100	mL	of	distilled	water	to	get	0.5	N	HCl.	
Chloroform	(Sdfine‐Chem	limited,	Mumbai).	
	
2.2.3.	Method	C	
	
0.001M	 Ammonium	 molybdate:	 Prepared	 by	 dissolving	
123.6	 mg	 of	 ammonium	 molybdate	 (Sdfine‐Chem	 limited,	
Mumbai)	 in	 50	 mL	 of	 distilled	 water	 in	 a	 100	 mL	 volumetric	
flask,	then	the	volume	was	diluted	up	to	the	mark	with	distilled	
water.	10%	Ammonium	thiocyanate:	Prepared	by	dissolving	10	
g	 of	 ammonium	 thiocyanate	 (Sdfine‐Chem	 limited,	Mumbai)	 in	
100	 mL	 of	 distilled	 water.	 10%	 Ascorbic	 acid:	 Prepared	 by	
dissolving	10	g	of	ascorbic	acid	(Sdfine‐Chem	 limited,	Mumbai)	
in	 100	 mL	 of	 distilled	 water.	 5%	 Sodium	 lauryl	 sulphate:	
Prepared	 by	 dissolving	 5	 g	 of	 sodium	 lauryl	 sulphate	 (Sdfine‐
Chem	 limited,	 Mumbai)	 in	 100	 mL	 of	 distilled	 water.	 3	 M	
Hydrochloric	 acid:	 10.95	mL	of	HCl	 (Fisher	 Scientific,	Mumbai)	
was	added	to	100	mL	of	distilled	water	to	get	3	M	HCl.	
	
2.3.	Doxofylline	tablet	dosage	forms	
	
The	 following	 dosage	 forms	 containing	 DFL	 was	 procured	
from	the	 local	pharmacy	stores:	Doxobid	(400	mg,	Reddy’s	Lab,	
Hyderabad),	Synasma	(400	mg,	Ranbaxy,	Mumbai),	Doxfree	(400	
mg,	Maceleods	pharmaceuticals,	Mumbai).	
	
2.4.	Preparation	of	stock	and	working	standard	drug	
solutions	
	
Pharmaceutical	 grade	 DFL	 was	 kindly	 gifted	 by	 local	
pharmaceutical	 industry.	 A	 stock	 standard	 solution	 containing				
1	mg/mL	 of	 DFL	was	 prepared	 in	 chloroform	 (method	 A)	 and	
water	(methods	B	&	C).	Working	standard	solution	equivalent	to	
200	μg/mL	(methods	A	&	B)	and	100	μg/mL	(method	C)	of	DFL	
was	 obtained	 by	 appropriate	 dilution	 of	 stock	 solution	 by	
chloroform	(method	A)	and	water	(method	B	&	C).	
	
2.5.	General	assay	procedure	
	
2.5.1.	Method	A	
	
Into	 a	 series	 of	 10	 mL	 volumetric	 flasks,	 volumes	 (0.2‐1.6	
mL)	of	DFL	standard	solution	(200	μg/mL)	equivalent	to	4‐32	μg	
of	 the	 drug	 were	 transferred.	 To	 each	 flask,	 1.5	 mL	 of	 0.2%										
p‐chloranilic	acid	was	added	and	brought	up	to	the	volume	with	
chloroform.	The	absorbance	of	the	pink	colored	product	formed	
at	 room	 temperature	 (25±1°C)	 was	 measured	 after	 20	 min	 of	
mixing	at	540	nm	against	 the	 reagent	blank	prepared	similarly	
omitting	the	drug.	The	standard	calibration	curve	was	prepared	
to	calculate	the	amount	of	the	analyte	drug	in	unknown	samples.	
	
2.5.2.	Method	B	
	
Into	a	series	of	100	mL	separating	funnels,	volumes	(0.2‐1.6	
mL)	of	DFL	standard	solution	(200	μg/mL)	equivalent	to	4‐32	μg	
of	the	drug,	0.5	mL	of	0.5	N	HCl	and	1.5	mL	0.2%	bromophenol	
blue	were	transferred	and	mixed	well.	The	funnels	were	shaken	
vigorously	with	2	×	5	mL	chloroform	for	2	min,	and	then	allowed	
to	 stand	 for	 clear	 separation	 of	 the	 two	phases.	 The	 separated	
organic	phase	was	transferred	to	a	10	mL	volumetric	flask.	Then	
the	extract	was	made	up	to	the	mark	with	chloroform	and	mixed	
well.	The	absorbance	of	the	organic	phase	was	measured	at	390	
nm	against	a	reagent	blank	prepared	similarly	omitting	the	drug.	
The	 standard	 calibration	 curve	 was	 prepared	 to	 calculate	 the	
amount	of	the	analyte	drug	in	unknown	samples.	
	
2.5.3.	Method	C	
	
Into	 a	 series	 of	 10	 mL	 volumetric	 flasks,	 volumes	 (0.2‐1.6	
mL)	of	DFL	standard	solution	(100	μg/mL)	equivalent	to	2‐16	μg	
of	 the	 drug	 were	 transferred.	 2.5	 mL	 of	 0.001	 M	 ammonium	
molybdate,	1	mL	3	M	HCl,	1	mL	10%	ascorbic	acid	solution	and		
2	 mL	 of	 10%	 ammonium	 thiocyanate	 were	 added	 in	 heating	
tubes.	 Left	 for	 15	minutes	 until	 complete	 formation	 of	Mo	 (V)	
SCN	complex,	1.5	mL	of	5%	sodium	 lauryl	sulphate	was	added,	
the	mixture	was	homogenized	by	shaking,	 immersed	in	a	water	
bath	at	50	°C	for	20	minutes,	then	cooled	to	room	temperature.	
The	mixture	was	diluted	to	volume	with	distilled	water	and	the	
absorbance	was	measured	at	690	nm	against	a	blank	prepared	
similarly	omitting	the	drug.	The	standard	calibration	curve	was	
prepared	 to	 calculate	 the	 amount	 of	 the	 analyte	 drug	 in	
unknown	samples.	
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2.5.4.	Reference	method		
	
Absorption	 maxima	 of	 DFL	 (20	 μg/mL)	 in	 0.1	 N	 HCl	 was	
determined	by	scanning	the	drug	solution	from	200‐400	nm	and	
was	 found	 to	 be	 at	 274	 nm.	 Into	 a	 series	 of	 10	mL	 volumetric	
flasks,	 volumes	 of	 DFL	 standard	 solution	 equivalent	 to	 4‐30	
μg/mL	of	the	drug	were	transferred	and	diluted	to	the	mark	with	
0.1	N	HCl.	The	absorbance	of	the	solution	was	measured	at	274	
nm	against	the	blank	prepared	similarly	omitting	the	drug.	The	
standard	calibration	curve	was	prepared	to	calculate	the	amount	
of	the	analyte	drug	in	unknown	samples.	
	
2.6.	Procedure	for	the	analysis	of	DFL	in	tablet	dosage	forms	
	
Ten	tablets	were	weighed	accurately	and	ground	into	a	fine	
powder.	An	amount	of	powder	equivalent	to	100	mg	of	DFL	was	
weighed	into	a	100	mL	volumetric	flask,	50	mL	of	the	chloroform	
(method	 A)	 or	 water	 (method	 B	 &	 C)	 or	 0.1	 N	 HCl	 (reference	
method)	 was	 added	 and	 shaken	 thoroughly	 for	 about	 10	min,	
then	 the	 volume	 was	 diluted	 up	 to	 the	 mark	 with	 the	 same	
solvents,	 mixed	 well	 and	 filtered	 using	 a	 quantitative	 filter	
paper.	 The	 filtered	 solution	was	 appropriately	diluted	with	 the	
respective	 solvents.	 Convenient	 aliquots	 were	 subjected	 to	
analysis	by	the	procedures	described	under	method	A,	B	&	C	and	
reference	method.	
	
3.	Results	and	discussion	
	
3.1.	Mechanism	of	the	reaction	
	
3.1.1.	Method	A	
	
The	 results	 obtained	 in	 method	 A	 were	 due	 to	 the	 charge	
transfer	reaction	between	the	DFL	and	p‐chloranilic	acid	to	yield	
a	 pink	 colored	 product	 having	 maximum	 absorption	 at	 a	
wavelength	of	540	nm	against	the	corresponding	reagent	blank.	
p‐chloranilic	acid	is	a	π	electron	acceptor	as	a	result	of	the	strong	
electron	withdrawing	halo‐	 and	 cyano‐	 groups	 conjugated	with	
the	π‐system.	The	DFL	has	tertiary	amino	group,	which	act	as	n‐
electron	donor.	Therefore,	 the	DFL	react	with	electron	acceptor	
to	 form	 charge	 transfer	 complex	 or	 radical	 anions.	 The	 charge	
transfer	complexes	are	formed	through	the	lone	pair	of	electrons	
donated	 by	 the	 DFL	 as	 n‐donor	 and	 the	 p‐chloranilic	 as	 an	
electron	acceptor	in	which	a	partial	 ionic	bond	was	assumed	to	
be	 formed.	 This	 interaction	 was	 particularly	 strong	 on	 using						
p‐chloranilic	so	that	it	involves	a	complete	transfer	of	electronic	
charge	with	the	formation	of	a	 free	radical	anion.	These	radical	
anions	 formed	 were	 the	 predominant	 chromogens	 in	 the	
reaction.	 The	 dissociation	 of	 the	 donor‐acceptor	 complex	 in	
those	reactions	was	promoted	by	the	high	ionizing	power	of	the	
solvent,	 chloroform.	A	general	 reaction	mechanism	 is	proposed	
in	Scheme	1.	
	
3.1.2.	Method	B		
	
The	 results	obtained	 in	method	B	were	based	on	extractive	
spectrophotometry.	The	DFL	exhibits	basic	character	essentially	
due	to	the	presence	of	tertiary	amino	group.	DFL	involves	an	ion	
association	 complex	 formation	 with	 acidic	 dye	 bromophenol	
blue	 under	 acidic	 conditions,	 which	 is	 extractable	 with	
chloroform	 from	 the	 aqueous	phase,	 resulting	 in	 the	 formation	
of	 a	 yellow	 color	 solution	 having	 maximum	 absorption	 at	 a	
wavelength	of	390	nm	against	the	corresponding	reagent	blank.	
A	general	reaction	mechanism	is	proposed	in	Scheme	2.	
	
3.1.3.	Method	C	
	
The	results	obtained	in	method	C	were	due	to	the	formation	
of	ternary	complex	between	the	tertiary	amine	group	of	DFL	and	
molybdenum	 (V)	 thiocyanate	 binary	 complex	 through	 the	
protonated	nitrogen	atom	of	the	DFL.	The	reduction	probability	
of	Mo	(VI)	may	occur	by	ascorbic	acid	in	acidic	media	and	react	
with	thiocyanate	to	form	a	red	binary	Mo	(V)	SCN¯complex.		
The	 sensitivity	 and	 stability	 of	 the	 molybdenum	 (V)	
thiocyanate	 ion‐pair	 binary	 complex	 is	 enhanced	 by	 using	
ascorbic	acid.	
	
 
	
Scheme	1	
	
	
 
	
Scheme	2	
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Scheme	3	
	
	
The	protonated	form	of	DFL	forms	ternary	complex	with	Mo	
(SCN)‐6	 resulting	 in	 the	 formation	 of	 a	 colored	 solution	 having	
maximum	 absorption	 at	 690	 nm	 against	 the	 corresponding	
reagent	blank.	Sodium	lauryl	sulphate	increases	the	sensitivity	of	
the	 color	 and	 avoids	 extraction	 of	 the	 complex.	 A	 general	
reaction	mechanism	is	proposed	in	Scheme	3.	
	
3.2.	Determination	of	optimum	wavelength	(λmax)	of	the	
colored	products	
	
The	λmax	of	 the	 colored	products	produced	 in	methods	A,	B	
and	 C	 were	 determined	 by	 scanning	 them	 in	 the	 wavelength	
region	 of	 380‐760	 nm	 against	 a	 corresponding	 reagent	 blank.	
Under	the	optimized	experimental	conditions	each	reagent	blank	
showed	 negligible	 absorbance	 at	 the	 corresponding	 optimum	
wavelength.	The	λmax	 of	 the	 colored	products	were	 found	 to	be	
540,	390	and	690	nm	for	methods	A,	B	and	C,	respectively.	The	
absorption	 spectrum	 of	 the	 proposed	methods	 (A,	 B	 and	 C)	 is	
shown	in	Figure	2.	
	
	
	
Figure	 2.	 Absorption	 spectra	 of	 Doxofylline	 with	 (A).	 p‐chloranilic	 acid,	 (B).	
Bromophenol	blue	and	(C).	Molybdenum	(V)	thiocyanate	binary	complex.	
	
3.3.	Optimization	of	parameters		
	
The	factors	affecting	reaction	conditions	(Concentration	of	p‐
Chloranilic	 acid,	 solvent	 used	 for	 dilution,	 reaction	 time	 and	
temperature	 in	method	A;	Concentration	of	Bromophenol	blue,	
acidity	 and	 solvent	 used	 for	 extraction	 in	 method	 B;	
Concentrations	 of	 Ammonium	 molybdate,	 Ammonium	 thio‐
cyanate,	Ascorbic	acid,	Sodium	lauryl	sulphate,	acidity,	reaction	
time	and	 temperature	 in	method	C)	were	evaluated	by	altering	
each	 variable	 in	 turn	 while	 keeping	 the	 others	 constant	 and	
observing	the	effect	produced	on	the	absorbance	of	the	colored	
species.	 The	 optimum	values	 of	 the	 variables	were	maintained	
throughout	 the	 experiment	 to	 determine	 the	 concentration	 of	
DFL.	
	
3.3.1.	Method	A	
	
The	 color	 reaction	 was	 studied	 as	 a	 function	 of	 the	
concentration	of	p‐chloranilic	acid.	The	results	indicated	that	the	
maximum	color	was	obtained	with	1.5	mL	of	0.2	%	p‐chloranilic	
acid.	The	results	obtained	from	optimization	of	the	reaction	time	
indicated	that	complete	color	development	was	attained	after	20	
min	 at	 room	 temperature.	 Different	 diluting	 solvents	 like	
methanol,	 ethanol,	 propanol,	 butanol,	 acetonitrile	 and	
chloroform	 were	 tested	 for	 appropriate	 dilution.	 The	 highest	
color	 intensity	was	 attained	when	 chloroform	was	 used	 as	 the	
diluting	solvent.	
	
3.3.2.	Method	B	
	
The	optimization	experiments	have	revealed	 that	1.5	mL	of	
0.2%	 bromophenol	 blue	 was	 sufficient	 for	 covering	 the	 broad	
range	 of	 Beer’s	 law	 limit.	 Several	 organic	 solvents	 such	 as	
dichloromethane,	 chloroform,	 carbon	 tetrachloride	and	butanol	
were	 used	 for	 extracting	 the	 ion‐association	 complex.	
Chloroform	was	selected	because	of	its	higher	sensitivity	and	the	
considerably	 lower	 extraction	 of	 the	 dye.	 The	 effect	 of	 pH	 or	
acidity	of	the	aqueous	phase	on	the	ion	association	complex	was	
studied.	The	color	intensity	of	the	chloroform	extract	reached	a	
maximum	when	0.5	mL	of	0.5	N	HCl	was	used.	
	
3.3.3.	Method	C	
	
The	effect	of	volume	of	0.001	M	ammonium	molybdate	and	
10	%	ammonium	thiocyanate	on	 the	absorbance	of	 the	colored	
product	 was	 studied.	 The	 maximum	 absorbance	 was	 obtained	
with	2.5	mL	of	 ammonium	molybdate	 and	2	mL	of	 ammonium	
thiocyante.	The	optimum	temperature	and	time	required	for	the	
formation	of	 ion	pair	binary	(Mo	(V)	SCN)	complex	and	ternary	
(Mo	 (V)	 SCN‐drug)	 complex	 was	 15	 minutes	 at	 room	
temperature	and	20	minutes	at	50°C	 respectively.	1	mL	of	3	M	
HCl	provides	sufficient	acidity	 for	 the	 formation	of	Mo	 (V)	SCN	
complex.	 Sensitivity	 and	 stability	 of	 the	 molybdenum	 (v)	
thiocyanate	ion‐pair	binary	complex	is	enhanced	by	using	1	mL	
of	 10%	 ascorbic	 acid.	 To	 avoid	 the	 extraction	 problem	 and	 to	
increase	 sensitivity	 of	 the	 method,	 many	 surfactants	 were	
examined;	 sodium	 lauryl	 sulphate,	 methylcellulose,	
benzalkonium	 chloride	 and	 tween	 40,	 the	 results	 obtained	
rivaled	the	maximum	color	observed	in	the	presence	of	1.5	mL	of	
5%	sodium	lauryl	sulphate.	
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Table	1.	Quantitative	parameters	for	the	proposed	methods.	
Parameters	 Method	A	 Method	B	 Method	C	
λmax	(nm)	 540 390	 690
Beer’s	Limit	(µg/mL	)	 4‐32 4‐32	 2‐16
Molar	Absorbtivity	(L/	mole/	cm)	 0.7822x104	 0.8133x104	 1.357x104	
Sandell’s	sensitivity	
(µg	cm‐2/0.001	Absorbance	unit)	
0.0439	 0.0714	 0.0196	
Stability	of	colored	products	(hours)	 3.0	 2.5	 4.0	
Regression	equation	(Y=	mx	+	c)a	
Slope	(m)	 0.0228 0.015	 0.0502
Intercept	(c)	 ‐0.0035 ‐0.0021	 ‐0.0023
Correlation	coefficient	(r)	 0.9993 0.9997	 0.9996
LOD	(µg/mL)	 0.173 0.244	 0.080
LOQ	(µg/mL)	 0.526 0.740	 0.243
Standard	deviationb	 0.00120 0.00111	 0.00122
Relative	standard	deviation	(%)		 1.318	 0.916	 1.38	
%	Range	of	error		
(Confidence	Limits)	
	 	 	
0.05	level	 1.10	 0.766	 1.15	
0.01	level	 1.630 1.1277	 1.707
a	Y	=	mx	+	c,	where	Y	is	the	absorbance	and	x	is	the	concentration	of	drug	in	μg/mL.	
b	Average	of	six	determinations.	
	
Table	2.	Recovery	studies	by	standard	addition	method.	
Method	 Formulation	 Labeled	claim	(mg) Pure	drug	added	(mg) Found	±	S.D	(n=5)	 Recovery	(%) RSD
A	
Doxobid	 400	 10 409.06±0.543 99.77	 0.132
Synasma	 400	 10	 411.06±0.696	 100.02	 0.170	
Doxfree	 400	 10 411.26±0.928 100.30	 0.227
B	
Doxobid	 400	 10	 408.67±0.854	 99.67	 0.209	
Synasma	 400	 10 412.45±0.649	 100.59	 0.159
Doxfree	 400	 10	 410.15±0.624	 100.03	 0.153	
C	
Doxobid	 400	 10 410.79±0.612 100.19	 0.150
Synasma	 400	 10 409.68±0.593 99.92	 0.145
Doxfree	 400	 10 411.89±0.867 100.46	 0.212
	
	
3.4.	Validation	
	
Validation	was	carried	out	by	assessing	the	parameters	like	
linearity	range,	precision,	accuracy,	detection	and	quantification	
limits	 according	 to	 the	 International	 Conference	 on	
Harmonisation	 (ICH)	 guidelines	 for	 validation	 of	 analytical	
procedures.	
A	 linear	 correlation	was	 found	 between	 absorbance	 at	 λmax	
and	concentration	of	DFL	for	all	the	three	methods	(A,	B	and	C).	
The	graphs	showed	negligible	intercept	and	are	described	by	the	
equation:	
	
Y	=	a	+	bX		 	 	 	 	 						(1)	
	
where	Y	=	absorbance	of	1‐cm	layer	of	solution,	a	=	intercept,	b	=	
slope,	X	=	concentration	of	drug	in	μg/mL.	
The	 linearity	was	evaluated	by	 linear	regression	analysis	of	
the	 Beer’s	 law	 data	 by	 least‐square	 regression	 method,	 which	
was	 used	 to	 calculate	 the	 correlation	 coefficient,	 intercept	 and	
slope	of	the	regression	line	and	the	values	are	presented	in	Table	
1.	 The	 optical	 characteristics	 such	 as	 Beer’s	 law	 limits,	 molar	
absorptivity	 and	 Sandell’s	 sensitivity	 values	 of	 the	 proposed	
methods	were	calculated	and	are	summarized	in	Table	1.	
In	order	to	determine	the	intraday	accuracy	and	precision	of	
the	 proposed	 methods	 (A,	 B	 and	 C),	 solution	 containing	 fixed	
concentration	 (within	 the	 working	 limits)	 of	 the	 drug	 was	
prepared	 and	 analyzed	 in	 six	 replicates	 by	 the	 proposed	
methods	 under	 the	 optimized	 experimental	 conditions.	 The	
standard	deviation,	 relative	 standard	deviations	and	recoveries	
obtained	 in	 the	 intra	day	analyses	by	methods	A,	B	and	C	were	
calculated	and	are	summarized	in	Table	1.	The	relative	standard	
deviation	indicates	the	high	intra‐day	precision	of	the	methods.	
Regarding	 the	 accuracy	 evaluation,	 good	 recoveries	 were	
obtained	 (Table	 1).	 The	 percent	 recovery	 indicated	 good	
accuracy	 and	 an	 agreement	 between	 the	 theoretical	 value	 and	
the	real	value	of	concentration.	Thus	the	proposed	methods	are	
effective	for	the	determination	of	DFL.	
Sensitivity	 of	 the	 proposed	 methods	 was	 evaluated	 by	
calculating	 Limit	 of	 detection	 (LOD)	 and	 limit	 of	 quantification	
(LOQ).	LOD	is	the	lowest	detectable	concentration	of	the	analyte	
by	 the	 method	 while	 LOQ	 is	 the	 minimum	 quantifiable	
concentration.	LOD	and	LOQ	were	calculated	by	equations:	LOD	
=	δ	3.3/s	and	LOQ	=	δ	10/s,	respectively,	where	δ	is	the	standard	
deviation	of	blank	and	s	is	slope	of	calibration.	The	results	(Table	
1)	indicating	proposed	methods	are	highly	sensitive.	
The	 reliability	 and	accuracy	of	 the	proposed	methods	were	
further	 confirmed	 by	 performing	 recovery	 studies	 by	 standard	
addition	 method.	 To	 a	 fixed	 and	 known	 quantity	 of	 the	 pre‐
analyzed	tablet,	pure	drug	(10	mg)	was	added	and	the	total	was	
found	 by	 the	 proposed	 methods	 (A,	 B	 and	 C).	 The	 results	 of	
recovery	study	are	complied	 in	Table	2.	The	percent	recoveries	
of	the	pure	drug	added	was	quantitative	and	additionally	reveal	
the	fair	selectivity	of	the	method.	
	
3.5.	Application	of	 the	proposed	methods	 for	 the	analysis	of	
tablets	
	
The	 proposed	 methods	 (A,	 B	 and	 C)	 were	 successfully	
applied	to	the	determination	of	DFL	in	three	different	brands	of	
tablet	dosage	forms.	The	results	are	summarized	in	Table	3.	The	
results	obtained	were	statistically	compared	with	the	reference	
method	 [10]	 by	 applying	 the	 Student’s	 t‐test	 and	 F‐test	 for	
accuracy,	 precision	 respectively.	 The	 calculated	 t‐value	 and	 F‐
value	 at	 95%	 confidence	 level	 did	 not	 exceed	 the	 tabulated	
values	 of	 2.77	 and	 6.39,	 respectively,	 for	 eight	 degrees	 of	
freedom.	The	 tests	 indicate	 that	 there	 is	no	difference	between	
the	proposed	methods	and	the	reference	method	with	respect	to	
accuracy	and	precision.	
	
4.	Conclusion	
	
The	 methods	 reported	 for	 the	 estimation	 of	 DFL	 has	 the	
advantages	 of	 simplicity,	 sensitivity,	 accuracy	 and	 is	 associated	
with	 higher	 sensitivity	 and	 precision.	 The	 developed	
spectrophotometric	 methods	 are	 cheaper	 than	 the	 reported	
liquid	 chromatographic	 methods	 for	 analysis	 of	 DFL	 in	 the	
pharmaceutical	preparations.		
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Table	3.	Determination	of	doxofylline	in	pharmaceutical	formulations	using	the	proposed	and	reference	methods.	
Method	 Formulation	 Labeled	claim	(mg)	 Found	±	S.D	(n=5)	 Recovery	(%)	 F*	value	 t*	value	
Reference	
Doxobid	 400 399.80±0.569 99.95	 ‐‐‐‐	 ‐‐‐‐
Synasma	 400	 405.80±0.324	 101.45	 ‐‐‐‐	 ‐‐‐‐	
Doxfree	 400 400.24±0.445 100.06	 ‐‐‐‐	 ‐‐‐‐
A	
Doxobid	 400 398.75±0.648 99.68	 1.87	 0.34
Synasma	 400	 400.06±0.491	 100.01	 1.46	 0.67	
Doxfree	 400 405.05±0.594 101.26	 2.11	 0.58
B	
Doxobid	 400 396.45±0.496 99.11	 2.69	 0.82
Synasma	 400 406.25±0.378 101.56	 1.27	 0.39
Doxfree	 400	 389.45±0.516	 97.36	 1.84	 0.67	
C	
Doxobid	 400 399.84±0.660 99.96	 2.45	 0.76
Synasma	 400 402.16±0.473 100.54	 1.59	 0.43
Doxfree	 400	 397.56±0.333	 99.39	 1.39	 0.61	
*Tabulated	t	value	at	95	%	confidence	level	=	2.77	and	Tabulated	F	value	at	95%	confidence	level	=	6.39.	
	
	
The	non‐interference	of	tablet	excipients	makes	the	methods	
suitable	for	 the	estimation	of	 the	drug	 in	 tablets	and	hence	can	
be	used	for	routine	quality	control	of	DFL	formulations.	
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